Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2007.12.8298 on December 17 2007

Journal of Clinical Oncology, Vol 26, No 3 (January 20), 2008: pp. 440-446
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Canioni, D.
Right arrow Articles by Xerri, L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canioni, D.
Right arrow Articles by Xerri, L.

High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial

Danielle Canioni, Gilles Salles, Nicolas Mounier, Nicole Brousse, Marie Keuppens, Frank Morchhauser, Thierry Lamy, Anne Sonet, Marie-Christine Rousselet, Charles Foussard, Luc Xerri

From the Department of Pathology, Assistance Publique-Hopitaux de Paris, Hôpital Necker-Enfants Malades; Université Paris-Descartes, Paris; Department of Hematology, Hospices Civils de Lyon; Université Lyon 1, Lyon; Department of Hematology, Centre Hospitalo-Universitaire, Nice; Department of Hematology, Centre Hospitalier, Lille; Department of Hematology, Centre Hospitalier, Rennes; Departments of Pathology and Hematology Hôpital d'Angers, Angers; Department of Bio-Pathology, Institut Paoli-Calmettes; Université de la Méditerranée, Marseille, France; and Department of Hematology, Hopital Universitaire de Mont-Godinne, Yvoir, Belgium

Corresponding author: Danielle Canioni, MD, Department of Pathology, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015, Paris, France; e-mail: danielle.canioni{at}nck.ap-hop-paris.fr

Purpose: High amounts of intratumoral macrophages have been shown to correlate with poor prognosis in patients with follicular lymphoma (FL) treated with chemotherapy without rituximab. We tried to establish whether intratumoral macrophage count (MC) definitely is able to predict the outcome of FL patients in the rituximab era.

Patients and Methods: We analyzed immunohistochemical CD68 expression in 194 FL patients from the FL-2000 trial, randomly assigned to receive cyclophosphamide, doxorubicin, etoposide, prednisolone, and interferon (CHVP-I) or rituximab plus CHVP-I. Immunohistochemistry was performed on paraffin sections using anti-CD68 KP1 antibody, and stained macrophages were scored on high-power field (hpf) in either intrafollicular (IF) or extrafollicular (EF) areas.

Results: For IF MC, the best cutoff point was estimated at 10 macrophages/hpf. Low IF MC was significantly associated with a better event-free survival (EFS; P = .011). However, this effect was observed only in the CHVP-I arm (P = .012) and not in the rituximab plus CHVP-I arm. Using a cutoff of 15 IF MC, we found no significant association with EFS. For EF MC, fewer than 22 macrophages/hpf were associated with better EFS in the CHVP-I arm (P = .02) but not in the rituximab plus CHVP-I arm.

Conclusion: These results show that MC can predict outcome of FL patients and that rituximab is able to circumvent the unfavorable outcome associated with high MC.

published online ahead of print at www.jco.org on December 17, 2007.

Supported by the Programme Hospitalier de Recherche Clinique (Hospices Civils de Lyon, PHRC 2000-081) and the Ligue Nationale Contre le Cancer.

Presented in part at the Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
haematolHome page
N. A. Johnson and R. D. Gascoyne
Gene expression signatures in follicular lymphoma: are they ready for the clinic?
Haematologica, July 1, 2008; 93(7): 982 - 987.
[Full Text] [PDF]


Home page
BloodHome page
M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
Blood, May 1, 2008; 111(9): 4664 - 4667.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online